Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of “Hold” by Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $12.50.

PGEN has been the subject of several research analyst reports. HC Wainwright raised their price target on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Citizens Jmp raised their target price on Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Citigroup reissued an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st.

Insider Transactions at Precigen

In other Precigen news, insider Donald P. Lehr sold 29,131 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $4.36, for a total transaction of $127,011.16. Following the completion of the transaction, the insider owned 755,461 shares in the company, valued at $3,293,809.96. This trade represents a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Rutul R. Shah sold 42,924 shares of Precigen stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.85, for a total transaction of $251,105.40. Following the completion of the transaction, the chief operating officer owned 497,751 shares of the company’s stock, valued at $2,911,843.35. The trade was a 7.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 822,728 shares of company stock worth $4,422,853. Insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

Institutional investors have recently modified their holdings of the business. State of Wyoming bought a new position in Precigen in the 1st quarter worth approximately $27,000. NBC Securities Inc. purchased a new position in shares of Precigen in the fourth quarter valued at $38,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Precigen in the third quarter valued at $39,000. Royal Bank of Canada raised its stake in shares of Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,426 shares during the period. Finally, Russell Investments Group Ltd. bought a new stake in shares of Precigen during the 3rd quarter valued at $41,000. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Stock Performance

Shares of PGEN opened at $5.12 on Friday. The stock has a 50 day moving average of $4.67 and a 200 day moving average of $4.31. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -4.34 and a beta of 1.00. Precigen has a 12 month low of $1.47 and a 12 month high of $6.04. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.01. The business had revenue of $23.25 million for the quarter, compared to analysts’ expectations of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. As a group, sell-side analysts forecast that Precigen will post -0.02 earnings per share for the current year.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.